QIAGEN NV - NL0015002CX3 (Stock)
XETRA
| Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
|---|---|---|---|---|---|---|
40,975 EUR
|
-0,2677% | 16.07.2025 10:45 | 137,00 | 40,96 | 40,975 | 60,00 |
| Contact | |
|---|---|
|
|
QIAGEN NV Hulsterweg 82 5912 PL, Venlo, NL |
| Phone | +31-77-355-66-42 |
| Fax | + |
| qiagen@qiagen.com | |
| Internet | http://www.qiagen.com |
| IR Contact/PR Contact | Peer M. Schatz/- |
| Symbol | QGE3 |
| End of financial year | 31.12.2025 |
| Issued capital | 8.853.143.631,64 EUR |
| Shareholders | |
|---|---|
| Freefloat | 66,84% |
| Massachusetts Financial Services Co. | 8,74% |
| Wellington Management Co. LLP | 6,67% |
| Wellington Management International Ltd. | 3,62% |
| The Vanguard Group, Inc. | 2,79% |
| MFS Institutional Advisors, Inc. | 2,03% |
| Amundi Asset Management US, Inc. | 1,93% |
| BlackRock Fund Advisors | 1,91% |
| T. Rowe Price International Ltd. | 1,91% |
| Norges Bank Investment Management | 1,82% |
| EARNEST Partners LLC | 1,75% |
| Board | |
|---|---|
| Thierry Bernard | Chairman of Managing Board |
| Stephany Foster | Member of Executive Committee |
| Roland Sackers | Member of Executive Committee |
| Nitin Sood | Member of Executive Committee |
| Jean-Pascal Viola | Member of Executive Committee |
| Fernando Beils | Member of Executive Committee |
| Antonio Santos | Member of Executive Committee |
| Stephen Rusckowski | Chairman of Supervisory Board |
| Elizabeth Tallett | Member of Supervisory Board |
| Bert van Meurs | Member of Supervisory Board |
| Dr. Toralf Haag | Member of Supervisory Board |
| Dr. Ross Levine | Member of Supervisory Board |
| Dr. Metin Colpan | Member of Supervisory Board |
| Dr. Eva Pisa | Member of Supervisory Board |
| Eva van Pelt | Member of Supervisory Board |
| Activity Description |
|---|
|
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. |
© 2000 - 2025 UniCredit Bank Austria AG. Please read our terms and conditions
Implemented and powered by FactSet
Fond data is provided from Mountain-View Data Gmbh
Austria-HomePage Version 2.0.54
